氯沙坦钾片与氯沙坦氢氯噻嗪片的降压疗效对比及对高尿酸血症的影响
|
摘要
目的对比氯沙坦钾片、氯沙坦氢氯噻嗪片的降压疗效及对高尿酸血症的影响。方法择取我院2016年12月至2018年12月收治的226例高血压合并高尿酸血症患者为研究对象,根据患者入院时间先后顺序分为对照组和观察组,每组113例。对照组患者行氯沙坦钾片治疗,观察组患者行氯沙坦氢氯噻嗪片治疗。比较2组患者临床疗效、治疗前后血压水平、血尿酸水平、炎性因子水平、超敏C反应蛋白水平以及用药不良反应情况。结果观察组患者临床疗效95.58%显著高于对照组85.84%,差异有统计学意义(P<0.05);治疗前2组患者血压水平、血尿酸水平、炎性因子水平、超敏C反应蛋白水平差异无统计学意义(P>0.05);治疗后观察组患者血压水平、血尿酸水平、炎性因子水平、超敏C反应蛋白水平均低于对照组,且治疗后相比同组治疗前均更低,差异有统计学意义(P<0.05);观察组患者不良反应发生率3.54%,对照组患者不良反应发生率8.85%,差异无统计学意义(P>0.05)。结论氯沙坦氢氯噻嗪片治疗高血压合并高尿酸血症效果相比氯沙坦钾更理想,对患者临床症状改善更明显,且安全性较高,因此该种治疗方法值得在临床中进行推广应用。
Objective To compare the antihypertensive effects of losartan potassium tablets and losartan hydrochlorothiazide tablets and their effects on hyperuricemia. Methods A total of 226 hypertensive patients with hyperuricemia admitted to our hospital from December 2016 to December 2018 were selected as the research subjects.According to the time of admission, the patients were divided into control group and observation group, 113 cases in each group. The control group was treated with losartan potassium tablets, while the observation group was treated with losartan hydrochlorothiazide tablets. The clinical efficacy, blood pressure, serum uric acid, inflammatory factors,hypersensitive protein levels and adverse drug reactions were compared between the two groups before and after treatment. Results The clinical efficacy of the observation group was significantly higher than that of the control group(95.58% vs 85.84%, P <0.05). There was no significant difference in blood pressure, serum uric acid, inflammatory factors and hypersensitive protein levels between the two groups before treatment(P>0.05); after treatment, the blood pressure, serum uric acid, inflammatory factors and hypersensitive protein levels in the observation group were signifi-cantly higher than those in the control group(P<0.05). The levels were lower than those of the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions was 3.54% in the observation group and 8.85% in the control group, with no significant difference(P>0.05). Conclusion Losartan hydrochlorothiazide tablet is more effective than losartan potassium in the treatment of hypertension complicated with hyperuricemia. It can improve the clinical symptoms of patients more obviously and has higher safety. Therefore, it is worth popularizing and applying in clinic.
Objective To compare the antihypertensive effects of losartan potassium tablets and losartan hydrochlorothiazide tablets and their effects on hyperuricemia. Methods A total of 226 hypertensive patients with hyperuricemia admitted to our hospital from December 2016 to December 2018 were selected as the research subjects.According to the time of admission, the patients were divided into control group and observation group, 113 cases in each group. The control group was treated with losartan potassium tablets, while the observation group was treated with losartan hydrochlorothiazide tablets. The clinical efficacy, blood pressure, serum uric acid, inflammatory factors,hypersensitive protein levels and adverse drug reactions were compared between the two groups before and after treatment. Results The clinical efficacy of the observation group was significantly higher than that of the control group(95.58% vs 85.84%, P <0.05). There was no significant difference in blood pressure, serum uric acid, inflammatory factors and hypersensitive protein levels between the two groups before treatment(P>0.05); after treatment, the blood pressure, serum uric acid, inflammatory factors and hypersensitive protein levels in the observation group were signifi-cantly higher than those in the control group(P<0.05). The levels were lower than those of the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions was 3.54% in the observation group and 8.85% in the control group, with no significant difference(P>0.05). Conclusion Losartan hydrochlorothiazide tablet is more effective than losartan potassium in the treatment of hypertension complicated with hyperuricemia. It can improve the clinical symptoms of patients more obviously and has higher safety. Therefore, it is worth popularizing and applying in clinic.
引文
[1]王月涛.氯沙坦钾联合氨氯地平治疗原发性高血压合并高尿酸血症[J].北方药学,2018,15(12):6-7.
[2]陈立伟,韩凌,骆景光.苯磺酸氨氯地平与氯沙坦钾对原发性高血压合并高尿酸血症患者尿酸水平影响的研究[J].中国现代药物应用,2018,12(15):137-138.
[3]蒋丹宇.氯沙坦钾氢氯噻嗪片治疗老年原发性高血压的临床治疗效果研究[J].中国实用医药,2018,13(7):1-3.
[4]洪雁,赵梅.氯沙坦钾与坎地沙坦酯对原发性高血压伴高尿酸血症患者的临床疗效及内皮祖细胞的修复作用的对比分析[J].广西医科大学学报,2017,34(11):1621-1623.
[5]刘刚.氯沙坦钾对老年原发性高血压伴高尿酸血症的临床疗效及安全性评价[J].川北医学院学报,2017,32(5):791-793.
[6]王阳.氯沙坦和缬沙坦治疗高血压合并高尿酸血症的临床效果对比[J].中国医药指南,2017,15(15):131-132.
[7]朱岩.氯沙坦钾对老年原发性高血压伴高尿酸血症的临床疗效及安全性评价[J].双足与保健,2017,26(9):125-126.
[8]吴春霞.氯沙坦钾与左旋氨氯地平联合用药治疗高血压合并高尿酸血症的临床效果[J].中国社区医师,2017,33(10):37,39.
[2]陈立伟,韩凌,骆景光.苯磺酸氨氯地平与氯沙坦钾对原发性高血压合并高尿酸血症患者尿酸水平影响的研究[J].中国现代药物应用,2018,12(15):137-138.
[3]蒋丹宇.氯沙坦钾氢氯噻嗪片治疗老年原发性高血压的临床治疗效果研究[J].中国实用医药,2018,13(7):1-3.
[4]洪雁,赵梅.氯沙坦钾与坎地沙坦酯对原发性高血压伴高尿酸血症患者的临床疗效及内皮祖细胞的修复作用的对比分析[J].广西医科大学学报,2017,34(11):1621-1623.
[5]刘刚.氯沙坦钾对老年原发性高血压伴高尿酸血症的临床疗效及安全性评价[J].川北医学院学报,2017,32(5):791-793.
[6]王阳.氯沙坦和缬沙坦治疗高血压合并高尿酸血症的临床效果对比[J].中国医药指南,2017,15(15):131-132.
[7]朱岩.氯沙坦钾对老年原发性高血压伴高尿酸血症的临床疗效及安全性评价[J].双足与保健,2017,26(9):125-126.
[8]吴春霞.氯沙坦钾与左旋氨氯地平联合用药治疗高血压合并高尿酸血症的临床效果[J].中国社区医师,2017,33(10):37,39.